Clinical characteristics and prior therapies in patients with NLPHL: transformed vs nontransformed patients
| . | Transformed (17 patients) . | Nontransformed (205 patients) . | P value . |
|---|---|---|---|
| Median age at presentation (y) | 41.5 | 40 | .8 |
| Sex (male) | 13 (76%) | 133 (65%) | .4 |
| Stage at presentation | |||
| Limited stage | 11 (65%) | 155 (76%) | .37 |
| Advanced stage | 6 (35%) | 50 (24%) | |
| B symptoms | 2 (12%) | 8 (4%) | .6 |
| Extranodal disease | 2 (12%) | 5 (2%) | .1 |
| Splenic involvement* | 5 (29%) | 8 (4%) | .003† |
| Initial therapies | |||
| RT | 8 (47%) | 122 (60%) | .2 |
| CRT | 2 (12%) | 30 (14%) | |
| CT | 7 (41%) | 45 (22%) | |
| Observation | 0 (0%) | 8 (4%) | |
| Type of RT | |||
| IFRT | 3 (38%) | 38 (31%) | .7 |
| EFRT | 1 (12%) | 12 (10%) | |
| IMRT | 1 (12%) | 22 (18%) | |
| N/A | 3 (38%) | 50 (41%) | |
| Prior exposure | |||
| Any RT | 12 (71%) | 156 (76%) | .4 |
| Any chemotherapy | 11 (65%) | 88 (43%) | .09 |
| Initial rituximab | 1 (6%) | 9 (4%) | .5 |
| MOPP | 1 (6%) | 17 (8%) | .4 |
| ABVD | 8 (47%) | 72 (35%) | .4 |
| CHOP | 1 (6%) | 4 (2%) | .3 |
| ASCT | 1 (6%) | 7 (3%) | .3 |
| . | Transformed (17 patients) . | Nontransformed (205 patients) . | P value . |
|---|---|---|---|
| Median age at presentation (y) | 41.5 | 40 | .8 |
| Sex (male) | 13 (76%) | 133 (65%) | .4 |
| Stage at presentation | |||
| Limited stage | 11 (65%) | 155 (76%) | .37 |
| Advanced stage | 6 (35%) | 50 (24%) | |
| B symptoms | 2 (12%) | 8 (4%) | .6 |
| Extranodal disease | 2 (12%) | 5 (2%) | .1 |
| Splenic involvement* | 5 (29%) | 8 (4%) | .003† |
| Initial therapies | |||
| RT | 8 (47%) | 122 (60%) | .2 |
| CRT | 2 (12%) | 30 (14%) | |
| CT | 7 (41%) | 45 (22%) | |
| Observation | 0 (0%) | 8 (4%) | |
| Type of RT | |||
| IFRT | 3 (38%) | 38 (31%) | .7 |
| EFRT | 1 (12%) | 12 (10%) | |
| IMRT | 1 (12%) | 22 (18%) | |
| N/A | 3 (38%) | 50 (41%) | |
| Prior exposure | |||
| Any RT | 12 (71%) | 156 (76%) | .4 |
| Any chemotherapy | 11 (65%) | 88 (43%) | .09 |
| Initial rituximab | 1 (6%) | 9 (4%) | .5 |
| MOPP | 1 (6%) | 17 (8%) | .4 |
| ABVD | 8 (47%) | 72 (35%) | .4 |
| CHOP | 1 (6%) | 4 (2%) | .3 |
| ASCT | 1 (6%) | 7 (3%) | .3 |
ASCT, autologous stem cell transplantation; CRT, chemoradiation therapy; CT, chemotherapy; EFRT, extended-field radiation therapy; IFRT, involved-field radiation therapy; IMRT, intensity-modulated radiation therapy; NA, not available.
Data on splenic involvement were missing in 23 patients with nontransformed disease.
Bold text means P value is significant.